A Big Role for microRNAs in Gestational Diabetes Mellitus

Masete, Matladi; Dias, Stephanie; Malaza, Nompumelelo; Adam, Sheryl

doi:10.3389/fendo.2022.892587

Cited by 9 publications

(3 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Masete et al explored the connection between maternal diabetes and pregnancy complications, specifically in pregestational type 1 and type 2 diabetes mellitus. The review emphasized miRNAs' emerging role in pregnancy-related disorders as potential diagnostic and predictive biomarkers, stressing the need for comprehensive miRNA profiling in various maternal diabetes types [16]. Mavreli et al conducted a case-control study to identify differentially expressed miRNAs in first-trimester maternal plasma, aiming to predict spontaneous preterm delivery (sPTD).…”

Section: Resultsmentioning

confidence: 99%

MicroRNA Associations with Preterm Labor—A Systematic Review

Kondracka,

Stupak,

Rybak-Krzyszkowska

et al. 2024

IJMS

View full text Add to dashboard Cite

This systematic review delves into the connections between microRNAs and preterm labor, with a focus on identifying diagnostic and prognostic markers for this crucial pregnancy complication. Covering studies disseminated from 2018 to 2023, the review integrates discoveries from diverse pregnancy-related scenarios, encompassing gestational diabetes, hypertensive disorders and pregnancy loss. Through meticulous search strategies and rigorous quality assessments, 47 relevant studies were incorporated. The synthesis highlights the transformative potential of microRNAs as valuable diagnostic tools, offering promising avenues for early intervention. Notably, specific miRNAs demonstrate robust predictive capabilities. In conclusion, this comprehensive analysis lays the foundation for subsequent research, intervention strategies and improved outcomes in the realm of preterm labor.

show abstract

Section: Resultsmentioning

confidence: 99%

MicroRNA Associations with Preterm Labor—A Systematic Review

Kondracka,

Stupak,

Rybak-Krzyszkowska

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…10 As reported previously, many miRNAs such as miR-20a, miR-30d, and miR-125b, have functioned as promising diagnostic as well as therapeutic methods because of their relation with GDM. 11 As reported previously, miR-122 is involved in the progression of various diseases, such as liver disease, 12 cervical cancer, 13 and cardiovascular fibrosis and related diseases, 14 which can function as a potential specific biomarker or the potential therapeutic target of diseases. However, the expression and role of miR-122 in GDM patients are unclear.…”

Section: Introductionmentioning

confidence: 80%

Correlation between serum microRNA-122 and VEGF expression and pregnancy outcome in gestational diabetes mellitus patients

He,

Wang,

Wang

et al. 2023

Pak J Med Sci

View full text Add to dashboard Cite

Objective: Gestational diabetes mellitus (GDM) seriously influences the health of mothers and babies, and there are still no effective early diagnostic markers. Therefore, our study planned to probe the correlation between serum microRNA-122 and VEGF expression and pregnancy outcome in GDM patients. Methods: This was a retrospective study of the correlation between serum microRNA-122 and vascular endothelial growth factor (VEGF) expression and pregnancy outcome in GDM patients. Sixty GDM patients admitted to the Fourth Hospital of Shijiazhuang from January 2021 to October 2022 were included in the research group (RG), and another 60 healthy pregnant women were included in the control group (CG). Serum miR-122 and VEGF levels were quantified using quantitative real-time polymerase chain reaction. The value of miR-122 and VEGF in predicting adverse pregnancy outcomes was analyzed by receiver operating characteristic curve. Results: Serum miR-122 and VEGF levels in the RG were higher relative to the CG. The total occurrence of adverse pregnancy outcomes in the RG was higher relative to the CG (P<0.05). Serum miR-122 together with VEGF levels in the poor outcome group was higher relative to the good outcome group (P<0.05). ROC analysis revealed that miR-122 and VEGF could be used to predict adverse pregnancy outcome (P<0.0001). The area under the curve of miR-122 was 0.860, 95% confidence interval (CI) =0.793-0.926, and the area under the curve of VEGF was 0.780, 95% CI =0.694-0.866. Serum levels of miR-122, VEGF were positively related with abortion, preterm delivery, low birth weight infants, macrogenesis infants, and fetal development abnormalities (P<0.001). Conclusion: The higher serum miR-122 and VEGF levels in GDM patients with satisfactory blood glucose control, the greater the probability of adverse pregnancy outcome, which should be paid attention to by clinicians. doi: https://doi.org/10.12669/pjms.40.3.8467 How to cite this: He H, Wang Y, Wang H, Ma Y, Zhang P. Correlation between serum microRNA-122 and VEGF expression and pregnancy outcome in gestational diabetes mellitus patients. Pak J Med Sci. 2024;40(3):---------. doi: https://doi.org/10.12669/pjms.40.3.8467 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

“…There are few studies on preterm birth and long non-coding RNAs (lncRNAs) [ 10 , 11 , 12 , 13 ] or circular RNAs (circRNAs) [ 14 , 15 ], but the most studied ncRNAs in preterm birth are microribonucleic acids (miRNAs). There are a large number of independent studies searching for the association between miRNAs and common gestational disorders [ 16 , 17 ]. At the same time, there are significantly fewer studies on miRNA profiling in preterm birth than in other pregnancy pathologies, such as preeclampsia (PE).…”

Section: Introductionmentioning

confidence: 99%

Plasma miRNA Profile in High Risk of Preterm Birth during Early and Mid-Pregnancy

Илларионов

Pachuliia

Vashukova

et al. 2022

Genes

View full text Add to dashboard Cite

In recent years evidence has been accumulated showing that miRNAs can act as potential biomarkers or targets for therapy of preterm birth, one of the most important problems in modern obstetrics. We have performed a prospective study of the miRNA profile in the plasma during the first and second trimesters in pregnant women with high risk of preterm birth (n = 13 cases and n = 11 controls). For the study group plasma blood samples at 9–13 weeks before diagnosis and at 22–24 weeks after start of therapy were selected. Using high-throughput sequencing technology we detected differences in the levels of 15 miRNAs (3 upregulated—hsa-miR-122-5p, hsa-miR-34a-5p, hsa-miR-34c-5p; 12 downregulated—hsa-miR-487b-3p, hsa-miR-493-3p, hsa-miR-432-5p, hsa-miR-323b-3p, hsa-miR-369-3p, hsa-miR-134-5p, hsa-miR-431-5p, hsa-miR-485-5p, hsa-miR-382-5p, hsa-miR-369-5p, hsa-miR-485-3p, hsa-miR-127-3p) (log2(FC) ≥ 1.5; FDR ≤ 0.05) during the first trimester compared with the control (non-high-risk of preterm birth pregnant women). All downregulated miRNAs in the first trimester from the placenta-specific C14MC cluster. During the second trimester no differentially expressed miRNAs were found. Our results suggest that the miRNA profile in plasma during early pregnancy may predict a high risk of preterm birth, which is important in preventing gestational problems as early as possible.

show abstract

A Big Role for microRNAs in Gestational Diabetes Mellitus

Cited by 9 publications

References 95 publications

MicroRNA Associations with Preterm Labor—A Systematic Review

MicroRNA Associations with Preterm Labor—A Systematic Review

Correlation between serum microRNA-122 and VEGF expression and pregnancy outcome in gestational diabetes mellitus patients

Plasma miRNA Profile in High Risk of Preterm Birth during Early and Mid-Pregnancy

Contact Info

Product

Resources

About